Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Raw Materials (2017 - 2023)

Perspective Therapeutics' Raw Materials history spans 11 years, with the latest figure at $764000.0 for Q3 2023.

  • On a quarterly basis, Raw Materials fell 16.23% to $764000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $764000.0, a 16.23% decrease, with the full-year FY2022 number at $752000.0, changed N/A from a year prior.
  • Raw Materials hit $764000.0 in Q3 2023 for Perspective Therapeutics, down from $781000.0 in the prior quarter.
  • Over the last five years, Raw Materials for CATX hit a ceiling of $912000.0 in Q3 2022 and a floor of $330000.0 in Q3 2019.
  • Historically, Raw Materials has averaged $598105.3 across 5 years, with a median of $645000.0 in 2021.
  • Biggest five-year swings in Raw Materials: soared 98.69% in 2021 and later decreased 16.23% in 2023.
  • Tracing CATX's Raw Materials over 5 years: stood at $372000.0 in 2019, then rose by 20.43% to $448000.0 in 2020, then surged by 67.63% to $751000.0 in 2021, then increased by 0.13% to $752000.0 in 2022, then increased by 1.6% to $764000.0 in 2023.
  • Business Quant data shows Raw Materials for CATX at $764000.0 in Q3 2023, $781000.0 in Q2 2023, and $777000.0 in Q1 2023.